Terms: = Breast cancer AND PRRX1, ENSG00000116132, 5396
18 results:
1. Heterogeneity and transcriptional drivers of triple-negative breast cancer.
Jovanović B; Temko D; Stevens LE; Seehawer M; Fassl A; Murphy K; Anand J; Garza K; Gulvady A; Qiu X; Harper NW; Daniels VW; Xiao-Yun H; Ge JY; Alečković M; Pyrdol J; Hinohara K; Egri SB; Papanastasiou M; Vadhi R; Font-Tello A; Witwicki R; Peluffo G; Trinh A; Shu S; Diciaccio B; Ekram MB; Subedee A; Herbert ZT; Wucherpfennig KW; Letai AG; Jaffe JD; Sicinski P; Brown M; Dillon D; Long HW; Michor F; Polyak K
Cell Rep; 2023 Dec; 42(12):113564. PubMed ID: 38100350
[TBL] [Abstract] [Full Text] [Related]
2. NR2F1 Is a Barrier to Dissemination of Early-Stage breast cancer Cells.
Rodriguez-Tirado C; Kale N; Carlini MJ; Shrivastava N; Rodrigues AA; Khalil BD; Bravo-Cordero JJ; Hong Y; Alexander M; Ji J; Behbod F; Sosa MS
Cancer Res; 2022 Jun; 82(12):2313-2326. PubMed ID: 35471456
[TBL] [Abstract] [Full Text] [Related]
3. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing prrx1 mRNA.
Block CJ; Mitchell AV; Wu L; Glassbrook J; Craig D; Chen W; Dyson G; DeGracia D; Polin L; Ratnam M; Gibson H; Wu G
Oncogene; 2021 Nov; 40(46):6430-6442. PubMed ID: 34608266
[TBL] [Abstract] [Full Text] [Related]
4. The Association of Overall Annual Hospital Volume and Perioperative Outcomes following Free Flap breast Reconstruction.
Shammas RL; Ren Y; Thomas SM; Phillips BT; Hollenbeck ST; Greenup RA
Plast Reconstr Surg; 2021 Feb; 147(2):196e-206e. PubMed ID: 33565821
[TBL] [Abstract] [Full Text] [Related]
5. Paired‑related homeobox 1 overexpression promotes multidrug resistance via PTEN/PI3K/AKT signaling in MCF‑7 breast cancer cells.
Luo H; Cong S; Dong J; Jin L; Jiang D; Wang X; Chen Q; Li F
Mol Med Rep; 2020 Oct; 22(4):3183-3190. PubMed ID: 32945446
[TBL] [Abstract] [Full Text] [Related]
6. Failure of sentinel lymph node mapping in breast cancer patients qualified for treatment sparing axillary lymph nodes-Clinical importance and management strategy-One-center analysis.
Nowikiewicz T; Głowacka-Mrotek I; Tarkowska M; Nowikiewicz M; Zegarski W
Breast J; 2020 May; 26(5):873-881. PubMed ID: 31999025
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Wang X; Liu H; Maimaitiaili A; Zhao G; Li S; Lv Z; Wu D; Shi A; Guan X; Jia H; Li M; Song D; Kang L; Han B; Fu T; Yang M; Zhu Z; Du Y; Song Y; Hong J; Fan Z
Mol Genet Genomic Med; 2019 Jun; 7(6):e677. PubMed ID: 30968603
[TBL] [Abstract] [Full Text] [Related]
8. A SIRT1-centered circuitry regulates breast cancer stemness and metastasis.
Shi L; Tang X; Qian M; Liu Z; Meng F; Fu L; Wang Z; Zhu WG; Huang JD; Zhou Z; Liu B
Oncogene; 2018 Dec; 37(49):6299-6315. PubMed ID: 30038266
[TBL] [Abstract] [Full Text] [Related]
9. Contralateral Prophylactic Mastectomy with Immediate breast Reconstruction Increases Healthcare Utilization and Cost.
Boughey JC; Schilz SR; Van Houten HK; Zhu L; Habermann EB; Lemaine V
Ann Surg Oncol; 2017 Oct; 24(10):2957-2964. PubMed ID: 28766231
[TBL] [Abstract] [Full Text] [Related]
10. Transcription Factor Networks derived from breast cancer Stem Cells control the immune response in the Basal subtype.
da Silveira WA; Palma PVB; Sicchieri RD; Villacis RAR; Mandarano LRM; Oliveira TMG; Antonio HMR; Andrade JM; Muglia VF; Rogatto SR; Theillet C; du Manoir S; Tiezzi DG
Sci Rep; 2017 Jun; 7(1):2851. PubMed ID: 28588211
[TBL] [Abstract] [Full Text] [Related]
11. Silencing of prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract] [Full Text] [Related]
12. Optimal Surgical Management for Occult breast Carcinoma: A Meta-analysis.
Macedo FI; Eid JJ; Flynn J; Jacobs MJ; Mittal VK
Ann Surg Oncol; 2016 Jun; 23(6):1838-44. PubMed ID: 26832884
[TBL] [Abstract] [Full Text] [Related]
13. miR-655 suppresses epithelial-to-mesenchymal transition by targeting prrx1 in triple-negative breast cancer.
Lv ZD; Kong B; Liu XP; Jin LY; Dong Q; Li FN; Wang HB
J Cell Mol Med; 2016 May; 20(5):864-73. PubMed ID: 26820102
[TBL] [Abstract] [Full Text] [Related]
14. Derivation of a fifteen gene prognostic panel for six cancers.
Khirade MF; Lal G; Bapat SA
Sci Rep; 2015 Aug; 5():13248. PubMed ID: 26272668
[TBL] [Abstract] [Full Text] [Related]
15. Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer.
Takahashi Y; Sawada G; Kurashige J; Uchi R; Matsumura T; Ueo H; Takano Y; Akiyoshi S; Eguchi H; Sudo T; Sugimachi K; Doki Y; Mori M; Mimori K
Br J Cancer; 2013 Jul; 109(2):307-11. PubMed ID: 23807160
[TBL] [Abstract] [Full Text] [Related]
16. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer prrx1.
Ocaña OH; Córcoles R; Fabra A; Moreno-Bueno G; Acloque H; Vega S; Barrallo-Gimeno A; Cano A; Nieto MA
Cancer Cell; 2012 Dec; 22(6):709-24. PubMed ID: 23201163
[TBL] [Abstract] [Full Text] [Related]
17. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract] [Full Text] [Related]
18. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Elstrodt F; Hollestelle A; Nagel JH; Gorin M; Wasielewski M; van den Ouweland A; Merajver SD; Ethier SP; Schutte M
Cancer Res; 2006 Jan; 66(1):41-5. PubMed ID: 16397213
[TBL] [Abstract] [Full Text] [Related]
